US vs Türkiye full-body screening cost. The savings are real — but the honest question is whether a healthy person should get a full-body screen at all.
US self-pay executive screening versus a reported Türkiye bundle. The Türkiye figure is deliberately labeled a market estimate — no neutral source publishes a precise package price, so we don't state one as fact.
| Market | Price | Context | Source |
|---|---|---|---|
| United States (self-pay, executive) | $2,000–$5,000 | Broad bloodwork + MRI/CT/ultrasound bundle; midpoint near $3,500. Largely self-pay — the ACA only requires no-cost coverage for grade A/B preventive services. | OECD price-level context / pricing-db |
| Türkiye (bundled check-up, reported) | $400–$700 | Comprehensive check-up packages at JCI-accredited hospital groups, bundled. A market estimate, ~80% less — not a neutral published price. | Reported / market estimate (hedged) |
| US health spending / person / year | ~$13,800 | OECD Health at a Glance — context for why the same tests cost more here | OECD 2023/2024 |
| Türkiye health spending / person / year | < $2,500 | Same scan, same panel — the building, labor, and paperwork simply cost less | OECD 2023/2024 |
The savings are real and large — roughly 80% for the same scan and panel. But a cheaper full-body screen is only a good deal if the screen was worth doing in the first place, and for symptom-free people much of it may not be. The money question and the medicine question are separate.
A US self-pay 'executive' full-body screening runs roughly $2,000 to $5,000, with a midpoint near $3,500. In Türkiye the same kind of bundled check-up is reportedly a few hundred dollars — around $400 to $700, a market estimate roughly 80% less (OECD/KFF context). The Türkiye figure is a reported package range, not a neutral published price.
The gap is price, not quality. OECD data shows the US spends about $13,800 per person on health a year versus under $2,500 in Türkiye. A blood draw and an MRI are the same test everywhere; the facility, labor, and administrative costs are far lower abroad.
Not automatically for healthy people. The Cochrane review (2012, reaffirmed 2019) found that general health checks did not lower the risk of dying and mainly led to more diagnoses. A bigger panel of tests is not necessarily a better one — which is the honest question behind the price tag.
No. A 2019 systematic review (Kwee & Kwee) found that roughly a third of symptom-free people scanned get an incidental finding — most of them harmless, but each can trigger more tests, cost, and anxiety. The reviewers concluded whole-body MRI should not be offered to asymptomatic people outside research.
Not according to the evidence. The USPSTF, for example, rates PSA prostate-cancer screening grade C (an individual decision) and recommends against it for men 70+, because over-screening can cause more harm than benefit. 'More tests' can mean more false alarms, not more health.
Two groups. Americans priced out at home — uninsured adults are three to four times more likely to skip care over cost (KFF), and 36% of US adults skipped or delayed care over cost in the past year. And immigrant families who already travel home and add a check-up to the trip. For everyone, the value still depends on which tests are actually evidence-based.
An identical blood panel and MRI cost a fraction abroad because the US spends roughly $13,800 per person per year on health versus under $2,500 in Türkiye (OECD). That price gap is genuine. But a full-body screen is a bundle, and the honest value of the bundle depends entirely on which tests inside it are evidence-based for a person with no symptoms.
The Cochrane review of general health checks (2012, reaffirmed 2019) found they did not reduce the risk of dying and mainly increased the number of diagnoses. Whole-body MRI illustrates the trade-off: a 2019 systematic review found about a third of symptom-free people scanned receive an incidental finding, most harmless — and the reviewers concluded it should not be offered outside research. The USPSTF makes the same point for individual tests, rating PSA screening grade C and advising against it after 70.
None of that changes the affordability problem at home. KFF reports that 36% of US adults skipped or delayed needed care over cost in the past year, and uninsured adults are three to four times more likely to skip care for cost reasons. For people priced out, and for immigrant families already traveling home, adding a low-cost check-up abroad is a rational response — the key is choosing tests that are actually useful, not just cheap.
The $400–$700 Türkiye range is a reported bundle price at JCI-accredited hospital groups, triangulated from market figures rather than a neutral published tariff. The savings versus the US are real; the exact figure is honestly approximate. As always, this is a cost comparison, not medical advice — decide which screening is right with a qualified clinician before booking anything.
Wellness Vision does not book trips, sell screenings, or receive referrals. We do not recommend specific clinics, hospitals, or providers, and we name none. The data comes from the OECD, the Cochrane Library, peer-reviewed radiology research, the USPSTF, KFF, and the Commonwealth Fund. This is a cost comparison, not medical advice — talk to a qualified, licensed clinician about which screening tests are right for you before any decision.
Before you decide: a plain-English screening checklist (which full-body tests are evidence-based for healthy people, which mostly find harmless incidentals, and what a bundle abroad does and doesn't include) — direct via newsletter, no Apple or Google fee.
📋 Or get the free Medical Travel Cost Checklist — no email →
View provenance manifest for this video →
You shouldn't have to go broke to feel whole.
